2024-09-03 - Analysis Report
##  REGEN Stock Analysis

**Company Overview:** Regeneron Pharmaceuticals, Inc. (REGEN) is a leading biotechnology company focused on the development and commercialization of life-transforming medicines for serious diseases. 

**1. Performance Comparison:**

* **REGEN**'s cumulative return is 159.56%, significantly outperforming the S&P 500 (VOO) with a cumulative return of 89.66%. 
* **Outperformance:** REGEN has outperformed the S&P 500 by 69.9%. This represents a relative outperformance of 95.82% compared to its historical performance range.

**2. Recent Price Movement:**

* **Closing Price:** $1184.69
* **5-Day Moving Average:** $1192.81
* **20-Day Moving Average:** $1158.3
* **60-Day Moving Average:** $1090.18

The stock is currently trading above all three moving averages, indicating potential upward momentum.

**3. Technical Indicators:**

* **RSI (73.51):** Indicates the stock is in overbought territory, suggesting a potential pullback.
* **PPO (-0.17):** A negative value suggests a weakening momentum, potentially indicating a short-term correction.
* **Relative Divergence:** The recent 20-day relative divergence is -4.18, indicating a short-term downward trend.
* **Expected Return (3.13%):** Suggests a potential for up to a 3.13% return over the next five years, based on current investment amount.

**4. Recent Earnings and Outlook:**

| Date       | EPS      | Revenue     |
|------------|----------|-------------|
| 2024-08-01 | 13.25    | 3.55 B$     |
| 2024-05-02 | 6.7      | 3.15 B$     |
| 2023-11-02 | 9.48     | 3.36 B$     |
| 2023-08-03 | 9.05     | 3.16 B$     |
| 2024-08-01 | 9.05     | 3.16 B$     |

* The most recent earnings report for Q2 2024 (Aug 1, 2024) showed an EPS of 13.25, beating the estimated EPS of 10.5. 
* Revenue was also higher than expected, reaching 3.55 B$. 
* Overall, REGEN has been consistently exceeding analysts' expectations for both EPS and revenue.

**5.  Summary:**

REGEN stock has outperformed the S&P 500 significantly, with a strong track record of delivering strong earnings and exceeding analysts' estimates. However, recent technical indicators suggest potential short-term corrections due to overbought conditions and weakening momentum. While the stock is currently above its moving averages, indicating potential upward momentum, investors should monitor the price action closely and consider potential pullbacks. The positive expected return remains an attractive factor for long-term investors.

**6. Further Considerations:**

* **Industry Analysis:** Evaluate the overall biotechnology sector's performance and future prospects.
* **Competition:** Assess the competitive landscape and REGEN's market share in specific therapeutic areas.
* **Risk Factors:** Consider regulatory, patent, and research and development risks.
* **Long-Term Growth Potential:** Analyze REGEN's pipeline of new drugs and potential for future growth.
